Emergent BioSolutions Inc (EBS, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics. Emergent BioSolutions Inc has a market cap of $3.23 billion; its shares were traded at around $63.33 with a P/E ratio of 32.14 and P/S ratio of 4.59. Emergent BioSolutions Inc had annual average EBITDA growth of 11.30% over the past ten years.
For the last quarter Emergent BioSolutions Inc reported a revenue of $173.7 million, compared with the revenue of $149.4 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $782.4 million, an increase of 39.5% from last year. For the last five years Emergent BioSolutions Inc had an average revenue growth rate of 17.2% a year.
The reported diluted earnings per share was $1.22 for the year, a decline of 28.7% from the previous year. Over the last five years Emergent BioSolutions Inc had an EPS growth rate of 10.8% a year. The Emergent BioSolutions Inc had a decent operating margin of 11.48%, compared with the operating margin of 22.16% a year before. The 10-year historical median operating margin of Emergent BioSolutions Inc is 19.35%. The profitability rank of the company is 8 (out of 10).
At the end of the fiscal year, Emergent BioSolutions Inc has the cash and cash equivalents of $112.2 million, compared with $178.3 million in the previous year. The long term debt was $784.5 million, compared with $13.5 million in the previous year. The interest coverage to the debt is 9.1. Emergent BioSolutions Inc has a financial strength rank of 9 (out of 10).
At the current stock price of $63.33, Emergent BioSolutions Inc is traded at 82.9% premium to its historical median P/S valuation band of $34.63. The P/S ratio of the stock is 4.59, while the historical median P/S ratio is 2.50. The stock gained 28.22% during the past 12 months.
For the complete 20-year historical financial data of EBS, click here.
